HEC 80797Alternative Names: HEC80797
Latest Information Update: 25 Aug 2016
At a glance
- Originator HEC Pharm
- Class Antineoplastics
- Mechanism of Action Cyclin-dependent kinase 4 inhibitors; Cyclin-dependent kinase 6 inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Breast cancer; Mantle-cell lymphoma
Most Recent Events
- 25 Aug 2016 Preclinical trials in Mantle cell lymphoma in China (unspecified route) prior to August 2016 (HEC Pharm pipeline, August 2016)
- 25 Aug 2016 Preclinical trials in Breast cancer in China (unspecified route) prior to August 2016 (HEC Pharm pipeline, August 2016)